A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.

about

Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients.

P2860

Q41526288-46F683BD-9572-4306-B1B1-714F928D2F72

P2860

A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.

Item

http://www.wikidata.org/entity/Q38378485

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

A Pharmacometric Framework for ...... Renal Cell Carcinoma Patients.

@en

type

Item

label

A Pharmacometric Framework for ...... Renal Cell Carcinoma Patients.

@en

prefLabel

A Pharmacometric Framework for ...... Renal Cell Carcinoma Patients.

@en

P1476

A Pharmacometric Framework for ...... Renal Cell Carcinoma Patients.

@en

P2093

E Schindler

http://www.w3.org/2001/XMLSchema#string

L E Friberg

http://www.w3.org/2001/XMLSchema#string

M A Amantea

http://www.w3.org/2001/XMLSchema#string

M O Karlsson

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.

Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.

A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.

A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.

A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.

Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

P304

373-382

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PSP4.12193

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28378918

http://www.w3.org/2001/XMLSchema#string

P932

5488123

http://www.w3.org/2001/XMLSchema#string

A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.

about

P2860

P2860

A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932